<DOC>
	<DOC>NCT00920959</DOC>
	<brief_summary>To demonstrate if once-daily dosing of ADVAIR 100/50 once-daily has superior efficacy and comparable safety compared with FP 100mcg once-daily in pediatric subjects 4 to 11 years of age with asthma.</brief_summary>
	<brief_title>Advair Pediatric Once-Daily</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Outpatients Asthma diagnosis Reversibility Shortacting betaagonist or asthma controlled medication use Lifethreatening asthma Specified asthma medications Chickenpox Drug allergy Respiratory infections Tobacco use Clinical laboratory abnormalities Ophthalmologic conditions Investigation medications Affiliation with investigator site</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>